Tiragolumab

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of OS, according to the agents’ manufacturer

In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more.

Tiragolumab plus atezolizumab added to chemotherapy did not extend survival outcomes as first-line therapy of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, interim results from a randomized study showed.

In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.

In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS, topline data showed.

In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.

A randomized phase 3 trial designed to assess the addition of tiragolumab to atezolizumab and chemotherapy for extensive-stage small cell lung cancer failed to meet its co-primary endpoint of PFS.

2020 presented many challenges, including the transformation of conferences and meetings into virtual events.

The FDA granted breakthrough therapy designation to tiragolumab combined with atezolizumab for the first-line treatment of patients with metastatic non-small cell lung cancer.